Ofirmev, a Cadence Pharmaceuticals product, is the first form of intravenous acetaminophen in the U.S. Cadence Pharmaceuticals is expected to launch the product in the early part of this year, according to the news report.
Read the news report about Ofirmev.
Read other coverage about FDA approvals:
– FDA Approves Mindray Medical Anesthesia System
– House Hears Arguments Over FDA’s Medical Device Approval Process
– 7 GI/Endoscopy Devices Receive FDA Approval
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.